DexCom Inc. (NASDAQ:DXCM) achieved fourth-quarter 2025 revenue of $1.26 billion, exceeding Wall Street's $1.25 billion estimate and marking a 12.6% year-over-year rise. The company also reported full-year revenues of $4.66 billion, outpacing its own guidance, and expects 2026 revenues between $5.16 billion and $5.25 billion as it rolls out new continuous glucose monitoring products and AI upgrades. This robust financial performance reinforces DexCom's status as a strong investment in the medical technology sector.
“DexCom Inc. (NASDAQ:DXCM) · is · one of the best medical technology stocks to invest in”
“DexCom Inc. (NASDAQ:DXCM) · shared · its Q4 2025 earnings · $1.26 billion in quarterly revenue”
“DexCom Inc. (NASDAQ:DXCM) · reported · $1.26 billion in quarterly revenue · well ahead of the $1.25 billion that Wall Street expected”
“DexCom Inc. (NASDAQ:DXCM) · reported · a 13% year over year growth”
“DexCom Inc. (NASDAQ:DXCM) · noted · that EPS for the quarter came in at $0.68 on a non-GAAP basis · surpassed expectations by $0.03”
“DexCom · reported · 2025 full year revenue · $4.662 billion”
“DexCom · exceeded · the company’s updated guidance range · $4.63-$4.65 billion”
“DexCom Inc. (NASDAQ:DXCM) · designs, manufactures, and sells · continuous glucose monitoring (CGM) systems · for people with diabetes”
“DexCom · has begun a · U.S. rollout of its G7 15-day continuous glucose monitoring system · true”
“DexCom · is preparing a · nationwide release of AI-enabled upgrades to its Stelo platform · true”
“DexCom · focuses on · continuous glucose monitoring technology · true”
“DexCom · reported full year 2025 sales of · US$4.66b · true”